Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuropharmacology ; 166: 107782, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-31756336

RESUMO

Although some studies have supported the effects of caffeine for treatment of Attention deficit and hyperactivity disorder (ADHD), there were no evidences about its effects at the neuronal level. In this study, we sought to find morphological alterations during in vitro development of frontal cortical neurons from Spontaneoulsy hypertensive rats (SHR, an ADHD rat model) and Wistar-Kyoto rats (WKY, control strain). Further, we investigated the effects of caffeine and adenosine A1 and A2A receptors (A1R and A2AR) signaling. Cultured cortical neurons from WKY and SHR were analyzed by immunostaining of microtubule-associated protein 2 (MAP-2) and tau protein after treatment with either caffeine, or A1R and A2AR agonists or antagonists. Besides, the involvement of PI3K and not PKA signaling was also assessed. Neurons from ADHD model displayed less neurite branching, shorter maximal neurite length and decreased axonal outgrowth. While caffeine recovered neurite branching and elongation from ADHD neurons via both PKA and PI3K signaling, A2AR agonist (CGS 21680) promoted more neurite branching via PKA signaling. The selective A2AR antagonist (SCH 58261) was efficient in recovering axonal outgrowth from ADHD neurons through PI3K and not PKA signaling. For the first time, frontal cortical neurons were isolated from ADHD model and they presented disturbances in the differentiation and outgrowth. By showing that caffeine and A2AR may act at neuronal level rescuing ADHD neurons outgrowth, our findings strengthen the potential of caffeine and A2AR receptors as an adjuvant for ADHD treatment.


Assuntos
Agonistas do Receptor A2 de Adenosina/uso terapêutico , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Cafeína/farmacologia , Lobo Frontal/efeitos dos fármacos , Lobo Frontal/embriologia , Neurônios/efeitos dos fármacos , Antagonistas do Receptor A1 de Adenosina/farmacologia , Agonistas do Receptor A2 de Adenosina/farmacologia , Animais , Transtorno do Deficit de Atenção com Hiperatividade/patologia , Células Cultivadas , Modelos Animais de Doenças , Feminino , Lobo Frontal/patologia , Neurônios/patologia , Gravidez , Ratos , Ratos Endogâmicos SHR , Ratos Endogâmicos WKY , Receptor A2A de Adenosina , Xantinas/farmacologia
2.
Neurosci Lett ; 474(2): 69-73, 2010 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-20211694

RESUMO

This study analyzes the relationship between extracellular purines and pain perception in humans. Cerebrospinal fluid (CSF) levels of purines and their metabolites were compared between patients displaying acute and/or chronic pain syndromes and control subjects. The CSF levels of IMP, inosine, guanosine and uric acid were significantly increased in the chronic pain group and correlated with pain severity (P<0.05). Patients displaying both chronic and acute pain presented similar changes in the CSF purines concentration (P<0.05). However, in the acute pain group, only CSF inosine and uric acid levels were significantly increased (P<0.05). These findings suggest that purines, in special inosine, guanosine and uric acid, are associated with the spinal mechanisms underlying nociception.


Assuntos
Limiar da Dor/fisiologia , Dor/líquido cefalorraquidiano , Dor/psicologia , Purinas/líquido cefalorraquidiano , Adolescente , Adulto , Idoso , Análise de Variância , Brasil , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medição da Dor/métodos , Estudos Prospectivos , Estatística como Assunto , Adulto Jovem
3.
J Pain ; 11(2): 131-41, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19734104

RESUMO

UNLABELLED: It is well known that adenine-based purines exert multiple effects on pain transmission. Less attention has been given, however, to the antinociceptive effects of guanine-based purines. The aim of this study was to investigate the effects of intraperitoneal administration of guanosine on a rat model of peripheral mononeuropathy. Additionally, investigation of the mechanism of action of guanosine, its general toxicity and measurements of central nervous system purine levels were performed. Rats received an intraperitoneal administration of vehicle (0.1 mM NaOH) or guanosine (up to 120 mg.kg(-1)) in an acute or chronic regimen. Guanosine significantly reduced thermal hyperalgesia on the ipsilateral side of the sciatic nerve ligation. Additionally, guanosine prevented locomotor deficits and body weight loss induced by the mononeuropathy. Acute systemic administration of guanosine caused an approximately 11-fold increase on central nervous system guanosine levels, but this effect was not observed after chronic treatment. Chronic guanosine administration prevented the increase on cortical glutamate uptake but not the decrease in spinal cord glutamate uptake induced by the mononeuropathy. No significant general toxicity was observed after chronic exposure to guanosine. This study provides new evidence on the mechanism of action of guanine-based purines, with guanosine presenting antinociceptive effects against a chronic pain model. PERSPECTIVE: This study provides a new role for guanosine: chronic pain modulation. Guanosine presents as a new target for future drug development and might be useful for treatment of neuropathic pain.


Assuntos
Analgésicos/uso terapêutico , Guanosina/uso terapêutico , Hiperalgesia/etiologia , Hiperalgesia/prevenção & controle , Ciática/complicações , Analgésicos/líquido cefalorraquidiano , Analgésicos/farmacologia , Animais , Sistema Nervoso Central/efeitos dos fármacos , Sistema Nervoso Central/metabolismo , Cromatografia Líquida de Alta Pressão/métodos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Comportamento Exploratório/efeitos dos fármacos , Ácido Glutâmico/metabolismo , Guanosina/líquido cefalorraquidiano , Guanosina/farmacologia , Hiperalgesia/patologia , Masculino , Transtornos dos Movimentos/etiologia , Transtornos dos Movimentos/prevenção & controle , Medição da Dor , Limiar da Dor/efeitos dos fármacos , Ratos , Ratos Wistar , Ciática/tratamento farmacológico , Estatísticas não Paramétricas , Fatores de Tempo
4.
Life Sci ; 76(7): 805-11, 2004 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-15581912

RESUMO

Bipolar disorder is a chronic and severe mental disorder. Recently, new animal models have emerged to further investigate underlying mechanisms of bipolar disorder such as ouabain-induced hyperactivity in rats. In this study, we investigated the cerebrospinal fluid levels of S100B protein as a putative marker of astrocytic activity in bipolar mania induced by intracerebroventricular administration of ouabain in rats. Ouabain induced a two-fold increase in crossing responses in the open field test and increased 30% the cerebrospinal fluid concentration of S100B, as compared to vehicle group. Our findings reinforce the role of astroglial cells in the pathogenesis of bipolar disorder and S100B protein as a marker of bipolar mania.


Assuntos
Comportamento Animal , Transtorno Bipolar/líquido cefalorraquidiano , Modelos Animais de Doenças , Inibidores Enzimáticos/toxicidade , Fatores de Crescimento Neural/líquido cefalorraquidiano , Ouabaína/toxicidade , Proteínas S100/líquido cefalorraquidiano , Animais , Comportamento Animal/efeitos dos fármacos , Transtorno Bipolar/etiologia , Comportamento Exploratório/efeitos dos fármacos , Masculino , Ratos , Ratos Wistar , Subunidade beta da Proteína Ligante de Cálcio S100
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...